Parotid Gland Removal: Patient Guide to Parotidectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Parotid gland removal, medically called a parotidectomy, is a surgical operation to remove part or all of the largest salivary gland in the body. The parotid glands sit just in front of and below each ear, one on each side of the face, and produce a large proportion of the saliva that keeps the mouth moist and aids digestion. Surgery becomes necessary when a lump, tumour, persistent infection, or ductal stone in the gland cannot be managed by any other means.

The operation is performed by a head and neck surgeon or an ENT (ear, nose and throat) specialist under general anaesthesia in a hospital setting. The surgeon makes a curved skin incision known as the Blair incision — it runs in the natural skin crease in front of the ear, curves gracefully behind the ear lobe, and continues downward into the upper neck crease. This placement takes advantage of natural skin shadows so the resulting scar is largely concealed.

The most important and technically demanding part of the operation is locating and protecting the facial nerve (cranial nerve VII). This nerve exits the skull through the mastoid bone just behind the ear and passes directly through the substance of the parotid gland, dividing into five branches that control every movement of the face — raising the eyebrows, closing the eyelids, smiling, and moving the lower lip. The surgeon identifies the main nerve trunk first and then traces each branch before removing any gland tissue.

Once the relevant portion of the gland is excised, a thin suction drain is placed beneath the wound to prevent fluid accumulating in the dead space. The drain is usually removed 24–48 hours post-operatively. The wound is closed in layers and most patients go home within one to two days. The majority of people return to light daily activities within two to three weeks.

Parotidectomy is recommended for a range of conditions, the majority of which are benign (non-cancerous) but still warrant removal to confirm the diagnosis, prevent growth, or eliminate symptoms:

• Pleomorphic adenoma (mixed parotid tumour): The most common parotid lump, accounting for approximately 70% of all cases. Despite being benign, it grows slowly and carries a risk of malignant transformation of 1–5% over 15 years if left untreated, making surgical excision the standard of care.
• Warthin's tumour (papillary cystadenoma lymphomatosum): The second most common benign tumour, seen particularly in older male smokers. It can occur simultaneously in both glands and is rarely malignant.
• Mucoepidermoid carcinoma and other malignant parotid tumours: Low-, intermediate-, and high-grade carcinomas require parotidectomy, often combined with neck dissection and post-operative radiotherapy.
• Chronic recurrent parotitis: Repeated episodes of painful gland swelling caused by salivary duct stones (sialolithiasis) or strictures that have not responded to conservative management, hydration, massage, or minimally invasive sialendoscopy.
• Parotid cysts: Large or symptomatic cysts that cause facial asymmetry, pain, or restricted mouth opening (trismus).
• HIV-associated lymphoepithelial cysts: Multiple bilateral parotid cysts linked to HIV infection, removed surgically when cosmetically disfiguring or repeatedly recurrent after aspiration.
• Lymph node metastases within the parotid: Skin cancers of the scalp or face (particularly melanoma and squamous cell carcinoma) frequently spread first to lymph nodes embedded within the parotid gland, requiring parotidectomy as part of the nodal clearance.

Pre-operative workup includes fine-needle aspiration cytology (FNAC) for tissue diagnosis and MRI with contrast to map the tumour's extent and its relation to the facial nerve.

Most patients with a confirmed or suspected parotid gland lesion are suitable for surgery, provided they are fit enough to tolerate general anaesthesia. The surgical team assesses each patient individually using the following steps:

• Clinical examination: The surgeon evaluates the lump's size, consistency, fixation to overlying skin or underlying tissues, and most importantly any pre-existing facial nerve weakness — which may suggest malignant nerve invasion.
• MRI with gadolinium contrast: The preferred imaging modality because it reliably shows whether the tumour is in the superficial or deep lobe, its relationship to the facial nerve, and any extension beyond the gland capsule. CT scan may be used additionally if bony erosion is suspected.
• Fine-needle aspiration cytology (FNAC): A thin needle is passed into the lump under ultrasound guidance to aspirate cells for microscopic examination. This distinguishes most benign lesions from malignant ones and guides the surgical plan, though some tumour types require surgical excision for definitive diagnosis.
• Anaesthetic fitness assessment: A pre-operative appointment with the anaesthetic team includes blood tests, ECG, blood pressure measurement, and a detailed medication review. Anticoagulant medications (aspirin, warfarin, DOACs) may need to be stopped before surgery.
• Shared decision-making: Small, asymptomatic benign tumours — especially in elderly or medically frail patients — may be offered active surveillance with annual MRI rather than immediate surgery, balancing operative risk against the slow growth rate of most benign parotid lesions.

Children with parotid lumps are assessed in specialist paediatric head and neck centres. There is no upper age limit for surgery — the decision is always individualised based on tumour biology, fitness, and the patient's informed preferences.

The scope of surgery is tailored to the size, location, and nature of the parotid lesion. The main surgical options are:

• Superficial parotidectomy: Removal of the superficial (lateral) lobe — the tissue lying above the plane of the facial nerve. This accounts for roughly 80% of the gland and is the procedure used for most benign tumours, including pleomorphic adenoma. The facial nerve is fully identified and all branches preserved. Operating time is typically 2–3 hours.
• Total parotidectomy: Removal of both the superficial and deep lobes, performed when the tumour involves the deep lobe or when a benign tumour recurs after a previous superficial excision. The facial nerve is still carefully preserved in a nerve-sparing total parotidectomy.
• Radical parotidectomy: Reserved for high-grade malignant tumours that have directly invaded the facial nerve. The nerve is sacrificed along with the gland. Reconstruction with a sural nerve cable graft — connecting the proximal stump to the distal branches — or a free muscle flap (such as a gracilis flap) may be performed simultaneously to partially restore facial movement over 12–18 months.
• Extracapsular dissection (ECD): A more limited approach used in selected expert centres for small, encapsulated benign tumours. It removes the tumour with a thin margin of surrounding parotid tissue rather than an entire lobe, resulting in shorter operating time and potentially lower complication rates while achieving equivalent recurrence rates in experienced hands.

During wound closure, the surgeon may place a temporoparietal fascia flap or inject autologous fat into the pre-auricular hollow to minimise the visible contour defect that parotidectomy can create in the cheek. All specimens are sent to the pathology laboratory for histological examination and margin assessment.

Surgical removal of a diseased parotid gland offers substantial benefits for the majority of patients:

• Definitive cure for benign tumours: Correct superficial parotidectomy for pleomorphic adenoma achieves a cure rate exceeding 95%, with recurrence rates below 5% at 10 years. Without surgery, pleomorphic adenomas grow inexorably and may transform to carcinoma ex pleomorphic adenoma, a much more dangerous cancer.
• Oncological control of cancer: Achieving clear surgical margins is the single most important prognostic factor for malignant salivary gland tumours. Combined with adjuvant radiotherapy where indicated, 5-year disease-free survival exceeds 85% for low-grade tumours and 60–70% for intermediate-grade lesions.
• Symptom relief: Excision eliminates recurrent episodes of painful gland swelling, facial pressure, restricted mouth opening, and repeated courses of antibiotics in patients with chronic parotitis or obstructive salivary disease.
• Definitive diagnosis: Surgery provides a complete tissue specimen for histological analysis, resolving diagnostic uncertainty in cases where FNAC is inconclusive and confirming the exact tumour subtype and grade to guide further management decisions.
• Elimination of anxiety: Many patients endure months of worry about a persistent facial lump. A confirmed benign pathology report after surgery — combined with low recurrence risk — removes the need for ongoing surveillance imaging and restores peace of mind.
• Preserved salivary function: Unilateral parotidectomy rarely causes clinically significant dry mouth because the contralateral parotid gland, the submandibular glands, and the sublingual glands collectively maintain adequate saliva output for comfortable chewing and swallowing.

Parotidectomy is safe in experienced hands but carries recognised complications that every patient should understand before consenting to the procedure:

• Facial nerve weakness: Transient partial weakness of facial muscles — affecting eye closure, eyebrow elevation, or the corner of the mouth — occurs in 20–40% of patients immediately after surgery due to nerve handling and retraction during tumour dissection. The vast majority recover full function within 3–6 months as nerve conduction returns. Permanent facial palsy from an anatomically preserved nerve occurs in fewer than 5% of cases at high-volume centres.
• Frey's syndrome (gustatory sweating): Approximately 30–50% of patients develop sweating and flushing on the cheek when eating, caused by misdirected regrowth of parasympathetic secretomotor nerve fibres into the sweat glands of the overlying skin. Effective treatments include antiperspirant cream application and botulinum toxin injections, which provide relief for 6–12 months per treatment. Surgical placement of a fascial barrier at the time of parotidectomy reduces the incidence substantially.
• Ear lobe numbness: The great auricular nerve — which provides sensation to the lower ear, ear lobe, and skin below the ear — runs directly across the surgical field and is typically divided or stretched during the Blair incision. Permanent numbness of the ear lobe is reported in 50–80% of patients, though most describe it as a minor inconvenience rather than a significant disability.
• Salivary fistula: A small collection of saliva that leaks from the cut gland tissue to the skin surface, appearing as a swelling in the wound that tastes salty. Incidence is under 5%. It generally resolves over 1–3 weeks with gentle pressure dressings and temporary dietary modification to reduce salivary secretion.
• Haematoma or seroma: Bleeding beneath the wound or serous fluid accumulation may require aspiration or surgical re-drainage in the early post-operative period.
• Pre-auricular contour defect: Removal of the gland tissue creates a visible hollow in front of and below the ear. Fat grafting or a sternocleidomastoid muscle turnover flap can restore the contour if this is cosmetically significant to the patient.

Recovery from parotid gland removal follows a predictable course for most patients. The key milestones are:

• Immediately after surgery (recovery room): Pain is well controlled with regular paracetamol and anti-inflammatory medication. A small suction drain is in place beneath the wound. The patient is encouraged to drink sips of water and eat a light soft meal the same evening.
• Day 1–2 (hospital discharge): The drain is removed once output drops below 20–30 mL per day, usually within 24–48 hours. A light dressing is applied and the patient goes home with written wound care instructions and oral analgesia.
• Week 1 (wound care): The wound should be kept dry for the first 48 hours. After that, gentle cleansing with soap and water is appropriate. Dissolvable sutures absorb naturally; non-dissolvable sutures are removed at the 5–7 day outpatient appointment. A soft diet reduces salivary stimulation and lowers fistula risk.
• Weeks 2–3 (return to activity): Light office work is usually possible from week 2 onwards. Strenuous exercise, heavy lifting, and contact sport should be avoided for 4–6 weeks. Driving is safe once the patient can perform an emergency stop without discomfort or distraction.
• Pathology review (1–2 weeks): Final histological results are discussed with the surgeon. If the excision is complete with clear margins and the diagnosis is benign, no further surgical treatment is needed. If malignancy is confirmed, a multidisciplinary oncology team meeting determines whether adjuvant radiotherapy or further surgery is required.
• Long-term follow-up: Benign tumour patients are typically reviewed at 6 weeks, 6 months, and 12 months before discharge from the surgical clinic. Malignant tumour patients enter a structured oncological follow-up programme with clinical review and periodic imaging for a minimum of 5 years.
• Facial physiotherapy: Patients with post-operative facial weakness benefit from early referral to a specialist facial physiotherapist for targeted mirror exercises and neuromuscular retraining, which accelerates the return of nerve function.

The cost of parotidectomy varies widely based on geography, hospital type, and the complexity of the individual case. Key cost drivers include:

• Extent of surgery: A straightforward superficial parotidectomy for a small benign tumour costs significantly less than a total or radical parotidectomy requiring nerve grafting, free flap reconstruction, or simultaneous neck dissection, all of which involve additional surgical teams, longer operating time, and specialised equipment.
• Intraoperative facial nerve monitoring: Continuous electromyographic (EMG) monitoring of the facial nerve is standard in accredited centres and adds to the procedural cost, but it is widely considered the most important safety measure in parotid surgery.
• Surgeon expertise and centre volume: High-volume head and neck units command higher surgical fees but typically deliver better outcomes — lower facial palsy rates, lower recurrence rates — which reduces the total cost of complications and revision surgery.
• Country of treatment: Approximate guide prices for superficial parotidectomy at private hospitals include: United States USD 12,000–22,000; United Kingdom GBP 6,000–12,000; Germany EUR 5,000–10,000; India (JCI-accredited) USD 2,500–5,000; Thailand USD 3,000–6,000; Turkey USD 2,000–4,500. These are indicative ranges only; individual quotes should be sought.
• Ancillary procedures: Fat grafting for cosmetic correction, additional histopathological testing (immunohistochemistry, molecular profiling), and radiotherapy for cancer patients add substantially to the overall treatment cost.
• Post-operative support: Facial physiotherapy, outpatient follow-up visits, and surveillance MRI scans for cancer patients represent ongoing costs that should be factored into the total treatment budget.

International patients should request fully itemised package quotations and confirm what is and is not included, particularly regarding pathology, anaesthesia, and post-operative nursing care.

Surgery is the definitive and most reliable treatment for most parotid gland conditions, but alternatives are available in specific clinical situations:

• Active surveillance (watchful waiting): Small, asymptomatic benign tumours — particularly pleomorphic adenomas under 2 cm in elderly or high-anaesthetic-risk patients — may be monitored with serial MRI (typically every 12 months) rather than operated upon immediately. This avoids surgical risk but requires long-term commitment and accepts a small cumulative risk of tumour growth and malignant transformation.
• Sialendoscopy: For parotid duct stones causing recurrent obstructive swelling in the absence of an underlying tumour, minimally invasive endoscopic stone retrieval through the duct opening (Stensen's duct papilla) is highly effective and entirely avoids open surgery. Small stones can be washed out, and larger ones fragmented with lithotripsy before removal.
• Radiotherapy: External beam radiotherapy (EBRT) or intensity-modulated radiotherapy (IMRT) may be used as primary therapy for parotid lymphoma or as an alternative for patients unfit for surgery due to medical comorbidities. It does not achieve equivalent tumour control to surgery for most salivary gland carcinomas and is not a substitute for parotidectomy in the routine management of benign or malignant epithelial parotid tumours.
• Botulinum toxin injections: Not a treatment for parotid tumours, but an effective, repeatable non-surgical option for managing Frey's syndrome after previous parotidectomy. Relief typically lasts 6–12 months per injection cycle.
• Aspiration and sclerotherapy: Some parotid cysts — especially HIV-related lymphoepithelial cysts — may be managed temporarily by aspiration or sclerosant injection, though surgical excision remains more durable for recurrent cases.